Parabilis Medicines, Inc. issued 4,166,666 shares of common stock to Regeneron Pharmaceuticals, Inc. for per share price equal to 90% of the initial public offering ("IPO") price of $20.00 per share.
“On June 9, 2026, Parabilis Medicines, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”), for the purchase of an aggregate of 4,166,666 shares (the “Shares”) of its voting common stock, par value $0.0001 (“Common Stock”), at a per share price equal to 90% of the initial public offering (“IPO”) price of $20.00 per share, through a private placement financing (the “Private Placement”), which took place concurrently with the IPO of the Company’s Common Stock. The Private Placement closed on June 11, 2026.”
Governance Changes
Parabilis Medicines, Inc.: Amended and restated bylaws to establish procedures for stockholder meetings, advance notice for proposals and nominations, and conform to amended certificate (effective 2026-06-09).
“the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Board and the Company’s stockholders, became effective as of the effectiveness of the Registration Statement”
Governance Changes
Parabilis Medicines, Inc.: Filed seventh amended and restated certificate of incorporation to authorize capital stock changes, eliminate references to prior series of preferred stock, and authorize undesignated preferred stock (effective 2026-06-11).
“the Company filed its seventh amended and restated certificate of incorporation (the “Amended and Restated Certificate”) with the Secretary of State of the State of Delaware”
Material Agreements
Parabilis Medicines, Inc. entered into Stock Purchase Agreement with Regeneron Pharmaceuticals, Inc. valued at aggregate of 4,166,666 shares at 90% of the $20.00 IPO price (effective 2026-06-09).
“On June 9, 2026, Parabilis Medicines, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”), for the purchase of an aggregate of 4,166,666 shares (the “Shares”) of its voting common stock, par value $0.0001 (“Common Stock”), at a per share price equal to 90% of the initial public offering (“IPO”) price of $20.00 per share, through a private placement financing (the “Private Placement”), which took place concurrently with the IPO of the Company’s Common Stock.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.